152 related articles for article (PubMed ID: 6215981)
21. In vivo selection of androgen-insensitive cells in R3327-G rat prostate tumors: diethylstilbestrol diphosphate treatment versus orchiectomy.
Pollack A; Block NL; Stover BJ; Irvin GL; Fuentes MP; Claflin AJ; Malinin TI
J Natl Cancer Inst; 1983 May; 70(5):907-14. PubMed ID: 6573535
[TBL] [Abstract][Full Text] [Related]
22. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.
Pavone-Macaluso M; Ingargiola GB; de Voogt H; Viggiano G; Barasolo E; Lardennois B; De Pauw M; Sylvester R
Prog Clin Biol Res; 1987; 243A():379-82. PubMed ID: 2958862
[No Abstract] [Full Text] [Related]
23. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
24. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
25. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
Koppan M; Nagy A; Schally AV; Arencibia JM; Plonowski A; Halmos G
Cancer Res; 1998 Sep; 58(18):4132-7. PubMed ID: 9751625
[TBL] [Abstract][Full Text] [Related]
26. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
[TBL] [Abstract][Full Text] [Related]
27. Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor.
Lokeshwar BL; Hurkadli KS; Sheth AR; Block NL
Cancer Res; 1993 Oct; 53(20):4855-9. PubMed ID: 8402673
[TBL] [Abstract][Full Text] [Related]
28. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
29. [Different behavior of the rat vas deferens of castrated animals and those treated with cyproterone acetate].
Hidalgo A; Casas-Tineo M; García de Boto MJ; Andrés-Trelles F
Rev Esp Fisiol; 1984 Jun; 40(2):159-63. PubMed ID: 6237395
[TBL] [Abstract][Full Text] [Related]
30. Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT.
Isaacs JT; Heston WD; Weissman RM; Coffey DS
Cancer Res; 1978 Nov; 38(11 Pt 2):4353-9. PubMed ID: 698976
[TBL] [Abstract][Full Text] [Related]
31. Is there a best endocrine management of prostatic carcinoma?
Robinson MR
Prog Clin Biol Res; 1988; 269():147-58. PubMed ID: 2969114
[No Abstract] [Full Text] [Related]
32. Hormone sensitivity of the R3327-G rat prostate adenocarcinoma: growth rate, DNA content, and hormone receptors.
Pollack A; Irvin GL; Block NL; Lipton RM; Stover BJ; Claflin AJ
Cancer Res; 1982 Jun; 42(6):2184-90. PubMed ID: 7074599
[TBL] [Abstract][Full Text] [Related]
33. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM
J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
[TBL] [Abstract][Full Text] [Related]
34. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
Miyake H; Pollak M; Gleave ME
Cancer Res; 2000 Jun; 60(11):3058-64. PubMed ID: 10850457
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.
Vieweg J; Rosenthal FM; Bannerji R; Heston WD; Fair WR; Gansbacher B; Gilboa E
Cancer Res; 1994 Apr; 54(7):1760-5. PubMed ID: 8137291
[TBL] [Abstract][Full Text] [Related]
36. Cholesterol ester metabolism in plasma during estrogen and antiandrogen treatment in men with carcinoma of the prostate.
Wallentin L; Varenhorst E
J Lab Clin Med; 1981 Dec; 98(6):906-16. PubMed ID: 6458644
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of endocrine therapy of prostate cancer by assessing tumor markers and hormone parameters. Hormonal "cross-over" treatment of false endocrine independent tumors.
Kraljić I; Tarle M
Prog Clin Biol Res; 1987; 243B():521-5. PubMed ID: 3659050
[No Abstract] [Full Text] [Related]
38. LNCaP model of human prostatic carcinoma.
Horoszewicz JS; Leong SS; Kawinski E; Karr JP; Rosenthal H; Chu TM; Mirand EA; Murphy GP
Cancer Res; 1983 Apr; 43(4):1809-18. PubMed ID: 6831420
[TBL] [Abstract][Full Text] [Related]
39. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
40. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide.
Vukanovic J; Isaacs JT
Cancer Res; 1995 Aug; 55(16):3517-20. PubMed ID: 7543015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
